IPP Bureau
Japan tops CPhI ‘API Quality’ ranking for second year
By IPP Bureau - March 13, 2022
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
New data show Lynparza demonstrated overall survival benefit in early breast cancer
By IPP Bureau - March 12, 2022
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Wipro and Pandorum partner to accelerate regenerative medicine with AI
By IPP Bureau - March 12, 2022
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Govt earmarks Rs 500 crore for pharma clusters and MSMEs
By IPP Bureau - March 12, 2022
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
By IPP Bureau - March 12, 2022
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
China approves BeiGene’s tislelizumab
By IPP Bureau - March 12, 2022
Tislelizumab is now approved for seven indications in China
BioPharma’s Herceptin biosimilar Phase 3 results positive
By IPP Bureau - March 12, 2022
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Study shows Pfizer vaccine moderately effective against Omicron for children 5-15
By IPP Bureau - March 12, 2022
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Moderna begins Phase 2 study of Omicron-specific bivalent booster
By IPP Bureau - March 11, 2022
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
By IPP Bureau - March 11, 2022
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine
By IPP Bureau - March 11, 2022
The money will be donated to the United Nations Children’s Fund (UNICEF)
Amity awards Dr Azad Moopen Doctorate for Philanthropy
By IPP Bureau - March 11, 2022
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Aurobindo Pharma trains its managers to be `future ready’
By IPP Bureau - March 11, 2022
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Emmes acquires Casimir, its fourth major acquisition
By IPP Bureau - March 11, 2022
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
By IPP Bureau - March 11, 2022
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
